Neogenomics INC (NEO) Shareholder Finemark National Bank & Trust Decreased Stake

NeoGenomics, Inc. (NASDAQ:NEO) Corporate LogoBig Money Sentiment increased to 1.6 in 2018 Q3. It has change of 0.65, from 2018Q2’s 0.95. The ratio improved due to NEO positioning: 12 sold and 40 reduced. 36 funds amassed stakes and 47 increased stakes. Investors holded 62.47 million in 2018Q2 but now own 73.06 million shares or 16.95% more. First Utd Bankshares holds 34,000 shs or 0.33% of its capital. Strs Ohio reported 0.02% in NeoGenomics, Inc. (NASDAQ:NEO). Old National Comml Bank In invested in 0.02% or 20,798 shs. Suntrust Banks Incorporated reported 38,931 shs. Rmb Cap Management Limited Liability Company has invested 0.07% in NeoGenomics, Inc. (NASDAQ:NEO). Prudential Fincl holds 0% or 14,600 shs in its capital. Qs Investors Llc invested in 0% or 47 shs. Jpmorgan Chase Com owns 0% invested in NeoGenomics, Inc. (NASDAQ:NEO) for 60,259 shs. Goldman Sachs Group Inc, New York-based fund reported 43,796 shs. State Board Of Administration Of Florida Retirement Systems invested in 68,034 shs or 0% of the stock. Hussman Strategic Advsrs reported 0.89% of its capital in NeoGenomics, Inc. (NASDAQ:NEO). New York-based Bnp Paribas Arbitrage has invested 0% in NeoGenomics, Inc. (NASDAQ:NEO). Dimensional Fund Advsrs LP owns 965,790 shs for 0.01% of their capital. Franklin owns 1.50M shs for 0.01% of their capital. Fulton National Bank Na holds 0.07% or 70,042 shs.

NEO registered $208.58 million net activity with 1 insider buy and 8 insider sales since July 30, 2018. Another trade for 5,000 shs valued at $80,800 was sold by TETRAULT LYNN A.. BALLIET JENNIFER also sold $1.15M worth of NeoGenomics, Inc. (NASDAQ:NEO) shs. On Monday, July 30 a trade for 203,500 shs valued at $2.85M was made by JONES STEVEN C. Johnson Kevin C had bought 26,000 shs worth $301,600. SHOVLIN ROBERT J. also sold $3.68 million worth of NeoGenomics, Inc. (NASDAQ:NEO) shs.

Finemark National Bank & Trust reduced its holdings by 92.46% in Neogenomics Inc (NEO), according to 2018Q3 Securities and Exchange filling. By selling 350,000 shares Finemark National Bank & Trust made the stock popped up with 4.81%. The institutional investor is holding 28,558 shares, compared to the 378,558 from the previous quarter. And the announced value of the health care company is $438,000 for the 2018Q3. Finemark National Bank & Trust has risen its stake in and also increased its holding in Citigroup Inc (NYSE:C) by 50,782 shares in the quarter, for a total of 137,598 shares.

Investors expect NeoGenomics, Inc. (NASDAQ:NEO)’s quarterly earnings on February, 20., as reported by RTT. Analysts predict $0.04 earnings per share. That’s $0.00 or 0.00 % from 2018’s earnings of $0.04. If earnings per share of $0.04 is revealed the profit of NEO could reach $3.78M giving it 94.81 P/E. Analysts at Wall Street see NeoGenomics, Inc.’s 0.00 % EPS growth compared to $0.04 earnings per share for previous quarter.

There’s a significant NeoGenomics, Inc. (NASDAQ:NEO) news published by Nasdaq.com. It’s an item titled: “Neo Lithium Announces Completion and Shipment of Pilot Plant to Argentina and Starts Drilling Campaign in the High-Grade Zone of the 3Q Project – Nasdaq” on January 14, 2019.

NeoGenomics, Inc. (NASDAQ:NEO) Ratings Coverage

A total of 3 analysts rate NeoGenomics (NASDAQ:NEO) as follows: 3 “Buy”, 0 “Hold” and 0 “Sell”. Š¢herefore 100% are bullish. (NASDAQ:NEO) has 3 ratings reports on Jan 14, 2019 according to StockzIntelligence. On Wednesday, October 31 the firm has “Outperform” rating by Raymond James given.

NeoGenomics, Inc. (NASDAQ:NEO) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.